testo-alternativo
Advances in Dermatology: Managing Complex Skin Conditions

Advancements in Dermatology: A Weekly Review

Dermatologia e Venerologia

Advances in Dermatology: Managing Complex Skin Conditions

This episode covers the latest research in dermatology, including hidradenitis suppurativa management, cutaneous squamous cell carcinoma guidelines, systemic photoprotection, and immune checkpoint inhibitor toxicities.

Login or Register to listen to this episode

Bibliography

1. Management of patients with hidradenitis suppurativa.
Authors: Martorell A, Caballero A, González Lama Y, et al.
Journal: Actas dermo-sifiliograficas, 2016 Sep
PMID: 28081768
DOI: 10.1016/S0001-7310(17)30007-8


2. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Authors: Wang DY, Salem JE, Cohen JV, et al.
Journal: JAMA oncology, 2018 Dec 1
PMID: 30242316
DOI: 10.1001/jamaoncol.2018.3923


3. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026.
Authors: Stratigos AJ, Dessinioti C, Garbe C, et al.
Journal: European journal of cancer (Oxford, England : 1990), 2026 Jul 26
PMID: 42263355
DOI: 10.1016/j.ejca.2026.116764


4. The role of surgery in hidradenitis suppurativa: expert-based holistic approaches.
Authors: Guillem P, Sayed CJ, Goldberg SR, et al.
Journal: Clinical and experimental dermatology, 2026 Jul 24
PMID: 41604416
DOI: 10.1093/ced/llag035


5. Systemic Photoprotection in Melanoma and Non-Melanoma Skin Cancer.
Authors: Hyeraci M, Papanikolau ES, Grimaldi M, et al.
Journal: Biomolecules, 2023 Jul 2
PMID: 37509103
DOI: 10.3390/biom13071067


6. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026.
Authors: Stratigos AJ, Dessinioti C, Garbe C, et al.
Journal: European journal of cancer (Oxford, England : 1990), 2026 Jul 26
PMID: 42248744
DOI: 10.1016/j.ejca.2026.116763

Comments

Please Login to leave a comment.

No comments yet.